Tacrolimus confers lower acute rejection rates and better renal allograft survival compared to cyclosporine

Table 1 Characteristics of patients in tacrolimus and cyclosporine group n (%)

Parameter	Cyclosporine n = 640	Tacrolimus n = 1195	P-value
Mean recipient age (yr)	49 ± 12	50 ± 13	0.059
Race			0.96
Non-African American	281 (44)	526 (44)
African-American	359 (56)	669 (56)
Sex			0.78
Male	371 (58)	693 (58)
Female	269 (42)	502 (42)
BMI	26 ± 7	28 ± 5	0.462
Etiology of kidney disease
DM	172 (26.9)	375 (31.4)	0.044
HTN	317 (49.5)	559 (46.8)	0.26
FSGS	36 (5.6)	78 (7.3)	0.177
IgA nephropathy	24 (3.8)	34 (2.8)	0.291
Polycystic kidney	63 (9.8)	89 (7.4)	0.076
History of DM	186 (29)	394 (33)	0.092
History of HTN	595 (93)	1135 (95)	0.122
History of heart disease	134 (21)	227 (19)	0.38
Years on dialysis	3 ± 2.4	3 ± 2.9	0.01
PRA	5%	17%	< 0.010
Preemptive transplant	122 (19)	239 (20)	0.49
Living donor transplant	122 (19)	179 (15)	0.27
CIT (h)	13 ± 9	16 ± 9	0.621
Mean donor age (yr)	31 ± 18	36 ± 16	< 0.010
KDRI	0.9 ± 0.6	1.3 ± 0.4	< 0.010
African-American donor	122 (19)	203 (17)	0.27
Induction therapy			< 0.010
Cytolytic agents	70 (11)	550 (46)
IL-2 receptor antagonist	570 (89)	645 (54)

DM: Diabetes mellitus; HTN: Hypertension; FSGS: Focal segmental glomerulosclerosis; PRA: Panel reactive antibody; CIT: Cold ischemia time; KDRI: Kidney donor risk index.